P R E S S W E B I N A R

A Vision for the Global Generic and Biosimilar Medicines Industry

IGBA Whitepaper

7th JULY 2021 / 14:00-15:00 (CEST)

Duration: 60 minutes | Participating audience: Global Media | Platform: Zoom

S P E A K E R S

Sudarshan Jain
Secretary General, Indian Pharmaceutical Alliance (IPA)
Chair, IGBA

Sudarshan has a strong passion for healthcare and the education sector. He is currently the Secretary General of Indian Pharmaceutical Alliance (IPA), Senior Advisor with APAX Partners and is also a Board member of multiple organizations. He is also the Chair of International Generic and Biosimilar Medicines Association (IGBA) for 2021. He has served in several leadership positions over the years and was earlier the Managing Director at Abbott Healthcare Solutions.

Sudarshan has a rich healthcare business experience of over 40 years which includes stints in Abbott, Johnson & Johnson and leading Indian companies. He has got extensive experience in field force management, brand building and overall business operations in healthcare companies. He has been associated with over 30 brands which are among the top 300 in the Indian Pharmaceutical industry. His experience covers Pharmaceutical, OTC, Hospital, Diagnostic & Nutrition business. He has received number of recognitions for his contributions within the company, with academic institutions and with industry associations. He is the first Indian recipient of the Global Chairman’s Award at Abbott.

Sudarshan has also served as Vice President of Organization of Pharmaceuticals Producers of India (OPPI) representing research based pharmaceutical companies. He is currently the member of the Board of Abbott India, Healthium Limited (APAX portfolio company), Zandu Chemicals Limited, member of the Advisory Board of Narsee Monjee University, Mumbai (NMIMS), Board Member of Indian Education Society (IES) and Charter Member of The Indus Entrepreneurs, Mumbai (TiE). He is a Certified Executive Coach from Coaching Foundation of India. He has also contributed in shaping the healthcare policy and improving access to healthcare in India.

Sudarshan is an alumni of St. Stephens College, Delhi and Indian Institute of Management, Ahmedabad.
Suzette Kox, M.Sc., Pharm.
Secretary General, IGBA

Suzette Kox was nominated in February 2019 as the first Secretary General of the International Generic and Biosimilar Medicines Association (IGBA). Universal access to cost-effective medicines has always been her motivation to work in the off-patent medicines sector.

Suzette has been involved with IGBA since its inception in 1997 in her capacity as Senior Director International and Coordinator of the Biosimilar Medicines Group at Medicines for Europe (formerly EGA). She was the first Chairperson of the IGBA Biosimilars Committee.

Before joining the European association in 2001, Suzette worked for 10 years in regulatory affairs and management for the German pharmaceutical company ratiopharm (now Teva) and, at the same time, acted as Chair of the EGA Regulatory & Scientific Affairs Committee.

Hanan J. Sboul, M.B.A., CAE
Secretary General, Jordanian Association of Pharmaceutical Manufacturers (JAPM) and Past Chair IGBA

Ms. Sboul has joined the Jordanian Association of Pharmaceutical Manufacturers JAPM in 2003 as a Secretary General. She represents the pharmaceutical industry sector locally, regionally, and internationally and plays a major role in shaping drug policies in Jordan as a current Board member of Jordan Food and Drug Administration JFDA and ex. Member of the Higher Committee for Drugs.

Before joining JAPM, Ms. Sboul has worked for Abt. Associates as a Deputy Chief of Party, Senior Pharmacist at Commercial Market Strategies, a USAID funded project for family planning and reproductive health in Jordan. She also worked at JFDA as Registration & Pricing Officer for 10 years.

Ms. Sboul is a member of USP Council of Convention, 2020-2025 Cycle, and an ex-member of the USP Convention Governance Committee in 2015-2020 Cycle. She is also a member of Higher Education Council, a member of Hamdi Mango Center for Academic Research, a vice chair of the Steering Committee for Jordan Pharmaceutical Center of Excellence, and an ex-Board Member of the Employment, Technical and Vocational Education Training Fund (ETVET), and Chair of the Steering Committee for Pharmaceutical Sector at Skills for Trade & Economic Diversification Project (STED) under ILO. Ms. Sboul is an ex-Board Member of Scientific Research Support Fund, ex-member of the Hashemite University Board of Trustees, Council of Pharmacy School at Jordan University and Council of Jordan University of Science & Technology.

Ms. Sboul received her MBA from Jordan University in Feb. 2000 and received her B.A in Pharmacy from Yarmouk University in Jordan in 1986. She was the first Jordanian association executive received the Certified Association Executive Certificate from the American Society for Association Executives in 2005.
David Wallace
Executive Editor, Informa Pharma Intelligence
Generics Bulletin's Executive Editor Dave Wallace has more than a decade of experience reporting on the global generics, biosimilars and value-added medicines industries. Bringing his education in law to bear on legislative and regulatory affairs, he also keeps a close eye on corporate strategy, personnel moves, and product pipelines. In his role as editor of Generics Bulletin he maintains close links with industry representatives and regularly appears at off-patent industry events. He also organizes and acts as a judge for the annual Global Generics & Biosimilars Awards.

Adrian van den Hoven
Director General, Medicines for Europe
Adrian van den Hoven joined Medicines for Europe as a Director General in September 2013. His priorities at Medicines for Europe are to stimulate competition in off-patent medicine markets, to foster market access for generic, biosimilar and value added medicines, to support policy measures for sustainable pricing, to promote high regulatory standards while ensuring that the associated costs can be integrated into market dynamics and to develop a coherent EU industrial strategy to support the long-term viability of the generic, biosimilar and value added medicines industries. Adrian is also the President of the European Medicines Verification Organisation (EMVO) for the implementation of serialisation against falsified medicines. Prior to joining Medicines for Europe, Adrian van den Hoven was Deputy-Director General of BUSINESSEUROPE where he was responsible for the International Relations department, covering trade negotiations and bilateral relations, and the Industry department, covering industrial, energy, environmental and research policy. He previously worked as an International Relations researcher and an adjunct professor in Italy (EUI), France (Nice) and Canada (Windsor). He obtained his doctorate in Political Science from the University of Nice, France in 2000.

Jonathan Kimball
Vice President of Trade and International Affairs, Association for Accessible Medicines (AAM)
Vice Chair, IGBA International Trade and Intellectual Property Committee
Jonathan Kimball is the Vice President of Trade and International Affairs at the Association for Accessible Medicines (AAM). He serves as senior strategist and advocate leading AAM’s trade, international affairs and supply chain advocacy efforts and represents the association and its member companies' interests before Congress and the Administration. Jonathan has more than 20 years of trade policy and international advocacy experience, having led Burson Cohn & Wolfe’s U.S. healthcare policy offering, managed advocacy efforts in Europe, the Middle East, Africa, and the Americas for the Pharmaceutical Research and Manufactures of America, and was Director for Central and Eastern Europe at the U.S. Department of Commerce.